EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A Comparative Review of Irish and Australian Expert Consensus on Criteria for Initiating and Continuing Reimbursed Janus Kinase Inhibitor Therapy in Alopecia Areata Patients

Aoife Boyle, John Bourke, Nicola Cooke, Mary Laing, Chantal Louise Cotter, Cathal O’Connor, Donna Cummins, Donal O’Kane, Caitriona Ryan, Alan D. Irvine, Ian McDonald, Meryl Thomas, Madeline Hankins, Laita Bokhari, Samantha Eisman, John Frewen, Rodney Sinclair, Dmitri Wall

Skin Appendage Disorders · 2026-10-07 · 1-1

DOI: 10.1159/sad/aesag017 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Janus kinase inhibitors (JAKis) are a multi-jurisdiction approved treatment for alopecia areata (AA). Despite obtaining the highest level of evidence of efficacy among available therapies, and carrying the strongest recommendations from international expert groups, access in Ireland, as in other countries such as Australia, has been restricted due to reimbursement challenges. This study replicates research conducted in Australia, which aimed to establish expert consensus on criteria for initiating and continuing reimbursed JAKis for AA. By comparing Irish and Australian findings, we aimed to provide a broader international perspective on the utility and need for reimbursed JAKis in the management of AA. Methods: A modified version of an eDelphi study developed by Australasian colleagues was developed with input from 12 Irish dermatologists with an interest in hair and scalp disorders to reflect an Irish perspective. The finalized survey, comprising 43 questions, was distributed electronically to members of the Irish Association of Dermatologists for participation. Consensus was defined as ≥75% agreement or disagreement. Results: Sixteen consultant dermatologists completed the survey. All agreed that JAK inhibitors are the preferred systemic treatment for patients with SALT scores >50. Several additional factors were deemed significant when assessing eligibility for JAKis, namely, refractory disease, psychosocial morbidity, rapid progression, impaired quality of life, disease relapse, ophiasis pattern, and poorly camouflaged hair loss. These findings closely mirrored the Australian consensus. Most experts also agreed that JAKi therapy should be re-evaluated at 12 months with treatment failure defined as

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →